Search
Altretamine
go.drugbank.com/drugs/DB00488ApprovedWithdrawnAn alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects.
7MW3711
go.drugbank.com/drugs/DB19298InvestigationalDeveloped by Mabwell, 7MW3711 is an antibody-drug conjugate targeting B7-H3.[L50918,L50923]
IR208
go.drugbank.com/drugs/DB05106InvestigationalIR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation. … It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial.
Sitamaquine
go.drugbank.com/drugs/DB04909InvestigationalSitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential
1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))
go.drugbank.com/drugs/DB11331ApprovedWithdrawnThe product was meant to compensate for alveolar surfactant deficiency and reduce to likelihood of alveolar collapse leading to acute respiratory collapse.
Rifalazil
go.drugbank.com/drugs/DB04934InvestigationalIt is being investigated by ActivBiotics for the treatment of various bacterial infections.
Tegoprazan
go.drugbank.com/drugs/DB16690InvestigationalTegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases. … [A234215, A234220] Tegoprazan’s strong and sustained effect is due to its ability to be slowly cleared from the gastric glands and exertion of effects independent of acid levels.
CoronaVac
go.drugbank.com/drugs/DB15806InvestigationalIt was developed by propagating the SARS-CoV-2 CN2 strain inside Vero Cells and inactivating it with B-propiolactone[A219481;A219758]. … CoronaVac, previously known as PiCoVacc, is a SARS-CoV-2 purified, inactivated, and adsorbed vaccine candidate developed by SinoVac Biotech Corporation[A219758].
Bioymifi
go.drugbank.com/drugs/DB17493ExperimentalUpon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent.
Quaternium-18
go.drugbank.com/drugs/DB11305ApprovedWithdrawnAcute oral and percutaneous toxicity tests in animals indicate that they exhibit little or no systemic toxic effects.